Loading quotes...
Forecast
The analysts' average price target is €31.33 (+34.12%). The median is €31.33 (+34.12%).
| Buy |
8 |
| Hold |
1 |
| Sell |
2 |
News Go to news feed
Tactile Systems Technology reports 12% revenue growth to $329.5M for 2025
Tactile Systems Technology posted 2025 revenue of $329.5 million, up 12%, and ended the year with $83.4 million in cash. The company acquired Lymphotec and plans to integrate its fluid-monitoring technology to enhance patient surveillance and commercial workflows. Investments in a new CRM and expanded sales headcount are driving productivity gains, while updated Medicare coverage criteria have improved access to the FlexiTouch system. For 2026 the company issued guidance of 8%–11% revenue growth but warned a new Medicare prior authorization requirement for pneumatic compression devices could create a short-term headwind. » More on finance.yahoo.com
Tactile Systems misses EPS forecast in Q2 2025 but beats revenue expectations
Tactile Systems Technology missed earnings expectations in the second quarter of 2025, reporting EPS of $0.14, while revenue came in above forecasts at $78.9 million. The respiratory product segment saw particularly strong growth, but the missed EPS and a decline in adjusted EBITDA led to a slight drop in the share price. The company remains optimistic for the full year and expects revenue growth of 6-8%. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 81.1m | 10.98% |
| Gross profit | 61.67m | 11.35% |
| Net profit | 6.32m | 9.63% |
| EBITDA | 10.09m | 9.47% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €544.99m |
Number of shares | 22.4m |
52-week high/low | €33.81 - €18.38 |
| Dividends | No |
Beta | 0.89 |
P/E ratio | 25.89 |
PEG ratio | 0.71 |
P/B ratio | 2.71 |
P/S ratio | 1.71 |
Company profile
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
| Name | Tactile Systems Technology Inc |
| CEO | Sheri Louise Dodd |
| Headquarters | Minneapolis,
mn USA |
| Website | |
| Sector | Consumer Discretionary |
| Industry | Household Durables |
| IPO | 28/07/2016 |
| Employees | 1,086 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | TCMD |
Frankfurt | 3L3.F |
Düsseldorf | 3L3.DU |
München | 3L3.MU |